Thymoglobulin and its use in renal transplantation: A review

American Journal of Nephrology

Volumn 37, Issue 6, 2013, Pages 586-601

  Thiyagarajan, Umasankar Mathuram ^a   Ponnuswamy, Amirthavarshini ^b   Bagul, Atul ^c  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b ROYAL CORNWALL HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Kidney failure; Rejection; Transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; ECULIZUMAB; GAMMA INTERFERON; INTERLEUKIN 10; THYMOCYTE ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY;

B LYMPHOCYTE; CANDIDIASIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; GRAFT SURVIVAL; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; SEPSIS; SURVIVAL; URINARY TRACT INFECTION; COMPLEMENT ACTIVATION; DOSE RESPONSE; DRUG MECHANISM; DRUG USE; GRAFT REJECTION; INFECTION; LIVING DONOR; LYMPHOCYTE DEPLETION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;

ANTILYMPHOCYTE SERUM; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 84878951527     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000351643     Document Type: Review

References (114)

1. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG: A randomized, double-blind-ed comparison of thymoglobulin versus At-gam for induction immunosuppressive ther-apy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018. (Pubitemid 29200852)
2. Sollinger H, Kaplan B, Pescovitz MD, Philo-sophe B, Roza A, Brayman K, Somberg K: Ba-siliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915-1919. (Pubitemid 34027863)
3. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahan L, Steinberg S, Woodle ES, Chan L, Ham JM, Schroeder TJ: Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29-37. (Pubitemid 28341164)
4. Hardinger KL, Schnitzler MA, Miller B, Low-ell JA, Shenoy S, Koch MJ, Enkvetchakul D, Ceriotti C, Brennan DC: Five-year follow-up of thymoglobulin versus Atgam induction in adult renal transplantation. Transplantation 2004; 78: 136-141.
5. Metchnikoff E: Etudes sur la résorption des cellules. Ann Inst Pasteur 1899; 13: 737-769.
6. Woodruff MFA AN: Effect of lymphocyte de-pletion by thoracic duct fistula and adminis-tration of antilymphocyte serum on the sur-vival of skin homografts in rats. Nature 1963; 200: 702.
7. Iwasaki Y, Porter KA, Amend JR, Marchioro TL, Zühlke V, Starzl TE: The preparation and testing of horse anti-dog and anti-human an-tilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet 1967; 124: 1-24.
8. Taylor HE, Ackman CFD, Horowitz I: Cana-dian clinical trial of antilymphocyte globulin in human renal allografts. Can Med Assoc J 1976; 115: 1205-1208. (Pubitemid 8027604)
9. Halloran P, Ludwin D, Aprile and the Cana-dian Multicentre Transplant Study Group: Comparison of antilymphocyte globulin-imuran, cyclosporine, and antilymphocyte globulin-cyclosporine therapy for cadaver re-nal transplantation. Transplant Proc 1985; 17: 1201-1203. (Pubitemid 15129660)
10. Hardy MA, Nowngrod R, Elberg A, Apple G: Use of ATG in steroid-resistant rejection. Transplantation 1980; 29: 162-164.l
11. Revillard JP: Immunopharmacology of thy-moglobulin. Graft 1999; 2:S6-S9.
12. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729. (Pubitemid 39665325)
13. Préville X, Nicolas L, Flacher M, Revillard J: A quantitative flow cytometry assay for the pre-clinical testing and pharmacological monit-oring of rabbit antilymphocyte globulins (rATG). J Immunol Methods 2000; 245: 45-54.
14. Kreis H, Mansouri R, Descamps JM, Danda-vino R, N'Guyen AT, Bach JF, Crosnier J: An-tithymocyte globulin in cadaver kidney trans-plantation: a randomized trial based on T-cell monitoring. Kidney Int 1981; 19: 438-444. (Pubitemid 11112625)
15. Mueller TF: Mechanisms of action of thymo-globulin. Transplantation 2007; 84: 5-10.
16. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N: Induction of Fas (Apo-1, CD95)-mediated apoptosis of acti-vated lymphocytes by polyclonal antithymo-cyte globulins. Blood 1998; 91: 2360-2368. (Pubitemid 28155510)
17. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP: Functional anti-bodies to leukocyte adhesion molecules in an-tithymocyte globulins. Transplantation 2003; 75: 657-662. (Pubitemid 36337364)
18. Préville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, Revillard JP: Mecha-nisms involved in antithymocyte globulin im-munosuppressive activity in a non-human primate model. Transplantation 2001; 71: 460-468. (Pubitemid 32175986)
19. Chappell D, Beiras-Fernandez A, Hammer C, Thein E: In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia reperfusion in a primate model. Transplantation 2006; 81: 552-558.
20. Clatworthy MR: Targeting B cells and anti-body in transplantation. Am J Transplant 2011; 11: 1359-1367.
21. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ: Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507-1515. (Pubitemid 40847581)
22. Bächler K, Amico P, Hönger G, Bielmann D, Hopfer H, Mihatsch MJ, Steiger J, Schaub S: Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low level donor-specific HLA antibodies. Am J Transplant 2010; 10: 1254-1262.
23. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD: Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody produc-tion. Am J Transplant 2009; 9: 201-209.
24. Mohty M: Mechanisms of action of antithy-mocyte globulin: T-cell depletion and be-yond. Leukemia 2007; 21: 1387-1394. (Pubitemid 46965279)
25. Gloor JM, Moore SB, Schneider BA, Degoey SR, Stegall MD: The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 2007; 84: 258-264. (Pubitemid 47205761)
26. Brayman K: New insights into the mecha-nisms of action of thymoglobulin. Transplan-tation 2007; 84:S3-S4. (Pubitemid 350294705)
27. Hammer C Thein E: Visualization of the ef-fect of polyclonal antithymocyte globulins on adhesion of leukocytes. Transplant Proc 2002; 34: 2486-2487. (Pubitemid 35299833)
28. Wood KJ Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210. (Pubitemid 37323205)
29. Sakaguchi S, Sakaguchi N: Regulatory T cells in immunologic self-tolerance and autoim-mune disease. Int Rev Immunol 2005; 24: 211-226. (Pubitemid 40991002)
30. + T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1643-1651. (Pubitemid 36687068)
31. + regulatory T cells in vitro. Blood 2008; 111: 3675-3683.
32. + regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-2853. (Pubitemid 44484674)
33. LaCorcia G, Swistak M, Lawendowski C, Duan S, Weeden T, Nahill S, Williams JM, Dzuris JL: Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppres-sive capabilities beyond cell depletion. Trans-plantation 2009; 87: 966-974.
34. Beiras-Fernandez A, Walther S, Thein E, Muenzing S, Hammer C: Influence of poly-clonal ATGs on expression of adhesion mol-ecules: an experimental study. Transplant Proc 2005; 37: 1944-1946. (Pubitemid 40790878)
35. Zeevi A, Husain S, Spichty KJ, Raza K, Wood-cock JB, Zaldonis D, Carruth LM, Kowalski RJ, Britz JA, McCurry KR: Recovery of func-tional memory T cells in lung transplant re-cipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7: 471-475. (Pubitemid 46096343)
36. Maki T, Gottschalk R, Wood ML, Monaco AP: Specific unresponsiveness to skin al-lografts in anti-lymphocyte serum-treated, marrow-injected mice: participation of donor marrow-derived suppressor T cells. J Immu-nol 1981; 127: 1433-1438. (Pubitemid 11021017)
37. Hale DA, Gottschalk R, Umemura A, Maki T, Monaco AP: Immunologic mechanisms in tolerance produced in mice with nonradia-tion-based lymphoablation and donor-spe-cific bone marrow. Transplantation 2002; 74: 477-484. (Pubitemid 34977675)
38. Hale DA, Gottschalk R, Umemura A, Maki T, Monaco AP: Establishment of stable multilin-eage hematopoietic chimerism and donor-specific tolerance without irradiation. Trans-plantation 2000; 69: 1242-1251. (Pubitemid 30238707)
39. + cells. Transplanta-tion 2008; 86: 1419-1426.
40. Guttmann RD, Caudrelier P, Alberici G, To-uraine JL: Pharmacokinetics, foreign protein immune response, cytokine release, and lym-phocyte subsets in patients receiving thymo-globulin and immunosuppression. Trans-plant Proc 1997; 29: 24-26.
41. Beiras-Fernandez A, Thein E, Chappel D, Gallego R, Fernandez-Roel D, Kemming G, Hammer C: Polyclonal anti-thymocyte glob-ulins influence apoptosis in reperfused tissues after ischaemia in anon-human primate mod-el. Transpl Int 2004; 17: 453-457. (Pubitemid 39362574)
42. Clesca P, Dirlando M, Park SI, García R, Fer-raz E, Pinheiro-Machado PG, Kushnaroff L, Tedesco-Silva H Jr, Medina-Pestana JO: Thy-moglobulin and rate of infectious complica-tions after transplantation. Transplant Proc 2007; 39: 463-464. (Pubitemid 46386245)
43. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G: Immuno-prophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
44. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D: Sequential protocols using basiliximab versus antithymocyte glob-ulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Trans-plantation 2004; 78: 584-590. (Pubitemid 39097106)
45. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D: Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977. (Pubitemid 44708016)
46. Mullen JC, Oreopoulos A, Lien DC, Bentley MJ, Modry DL, Stewart K, Winton TL, Jack-son K, Doucette K, Preiksaitis J, Halloran PF: A randomized, controlled trial of daclizumab vs. anti-thymocyte globulin induction for lung transplantation. J Heart Lung Trans-plant 2007; 26: 504-510. (Pubitemid 46602005)
47. Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Ber-gougnoux L, Touchard G: CMV infections af-ter two doses of daclizumab versus thymo-globulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant 2008; 23: 2024-2032. (Pubitemid 351768146)
48. Woodle ES, Peddi VR, Tomlanovich S, Mul-gaonkar S, Kuo PC: A prospective, random-ized, multicenter study evaluating early cor-ticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transpl 2010; 24: 73-83.
49. Massberg S, Messmer K: The nature of isch-emia/reperfusion injury. Transplant Proc 1998; 30: 4217-23.
50. Rabb H, Daniels F, O'Donnell M, Haq M, Saba SR, Keane W, Tang WW: Pathophysio-logical role of T lymphocytes in renal isch-emia-reperfusion injury in mice. Am J Physi-ol Renal Physiol 2000; 279:F525-F531.
51. Yokota N Daniels F, Crosson J, Rabb H: Pro-tective effect of T-cell depletion in murine re-nal ischemia-reperfusion injury. Transplan-tation 2002; 74: 759-763.
52. De Greef KE, Ysebaert DK, Dauwe S, Persy V, Vercauteren SR, Mey D, De Broe ME: Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia. Kidney Int 2001; 60: 1415-1427. (Pubitemid 32960035)
53. Wang S, Diao H, Guan Q, Cruikshank WW, Delovitch TL, Jevnikar AM, Du C: Decreased renal ischemia-reperfusion injury by IL-16 inactivation. Kidney Int 2008; 73: 318-323.
54. Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN: Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury. Am J Med Sci 2005; 329: 13-17. (Pubitemid 40096799)
55. Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, Chejfec G Cotler S, Oberholzer J, Testa G, Benedetti E: Thymoglobulin induction protects liver al-lografts from ischemia/reperfusion injury. Clin Transpl 2005; 19: 507-511. (Pubitemid 40990661)
56. Beiras-Fernandez A, Chappell D, Hammer C, Beiras A, Reichart B, Thein E: Impact of poly-clonal anti-thymocyte globulins on the ex-pression of adhesion and inflammation mol-ecules after ischemia-reperfusion injury. Transpl Immunol 2009; 20: 224-228.
57. Jang HR, Gandolfo MT, Ko GJ, Racusen L, Rabb H: The effect of murine anti-thymocyte globulin on experimental kidney warm isch-emia-reperfusion injury in mice. Transpl Im-munol 2009; 22: 44-54.
58. Goggins WC, Pascual MA, Powelson JA, Ma-gee C, Tolkoff-Rubin N, Farrell ML, Ko DS, Williams WW, Chandraker A, Delmonico FL, Auchincloss H, Cosimi AB: A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Trans-plantation 2003; 76: 798-802. (Pubitemid 37140222)
59. Patel SJ, Duhart BT Jr, Krauss AG, Moore LW, Egidi MF, Amiri HS, Gaber LW, Gaber AO: Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin in-duction. Transplantation 2008; 86: 313-320.
60. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, Charpentier B, Tou-chard G, Berthoux F, Merville P, Ouali N Squifflet JP, Bayle F, Wissing KM, Hazzan M: Daclizumab versus antithymocyte globu-lin in high-immunological-risk renal trans-plant recipients. J Am Soc Nephrol 2009; 20: 1365-1392.
61. Gjertson DW: Determinants of long-term survival of adult kidney transplants: a 1999 UNOS update. Clin Transpl 1999: 341-352.
62. Hariharan S: Long-term kidney transplant survival. Am J Kidney Dis 2001; 38: 44-50.
63. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Im-proved graft survival after renal transplanta-tion in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612. (Pubitemid 30118412)
64. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH: The im-pact of acute rejection episodes on long-term graft function and outcome in 1, 347 primary renal transplants treated by three cyclosporine regimens. Transplantation 1993; 56: 307-315. (Pubitemid 23239430)
65. Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S: Induc-tion treatment with rabbit antithymocyte globulin versus basiliximab in renal trans-plant recipients with planned early steroid withdrawal. Pharmacotherapy 2011; 31: 566-573.
66. Kamel MH, Mohan P, Little DM, Awan A, Hickey DP: Rabbit antithymocyte globulin as induction immunotherapy for pediatric de-ceased donor kidney transplantation. J Urol 2005; 174: 703-707. (Pubitemid 40981638)
67. Shenoy M, Roberts D, Plant ND, Lewis MA, Webb NJ: Antithymocyte treatment of ste-roid-resistant acute rejection in renal trans-plantation. Pediatr Nephrol 2011; 26: 815-818.
68. Tian JH, Wang X, Yang KH, Liu AP, Luo XF, Zhang J: Induction with and without antithy-mocyte globulin combined with cyclospo-rine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Transplant Proc 2009; 41: 3671-3676.
69. Emami S, Huang E, Kuo HT, Kamgar M, Bun-napradist S: Multivariate analysis of antibody induction therapy and their associated out-comes in live donor kidney transplantation in the recent era. Clin Transpl 2012; 26: 315-318.
70. Knight RJ, Kerman RH, Schoenberg L, Pod-der H, Van Buren CT, Katz S, Kahan BD: The selective use of basiliximab versus thymo-globulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft func-tion. Transplantation 2004; 78: 904-910. (Pubitemid 39298536)
71. Libório AB, Mendoza TR, Esmeraldo RM, Oliveira ML, Paes FJ, Silva Junior GB, Daher EF: Induction antibody therapy in renal transplantation using early steroid withdraw-al: long-term results comparing anti-IL-2 re-ceptor and anti-thymocyte globulin. Int Im-munopharmacol 2011; 11: 1832-1836.
72. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Es-quenazi V, Tzakis AG, Miller J: A randomized trial of three renal transplant induction anti-bodies: early comparison of tacrolimus, my-cophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-465. (Pubitemid 41209412)
73. Campbell SB, Hothersall E, Preston J, Brown AM, Hawley CM, Wall D, Griffin AD, Isbel NM, Nicol DL, Johnson DW: Frequency and severity of acute rejection in live-versus ca-daveric-donor renal transplants. Transplan-tation 2003; 76: 1452-1457. (Pubitemid 37467693)
74. Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR Jr, Copenhaver B, Bartlett ST: Should living-unrelated renal transplant recipients receive antibody induction? Re-sults of a clinical experience trial. Transplan-tation 2004; 77: 422-425. (Pubitemid 38209743)
75. Hardinger KL, Schnitzler MA, Koch MJ, Labile E, Stirnemann PM, Miller B, En-kvetchakul D, Brennan DC: Thymoglobulin induction is safe and effective in live donor renal transplantation: a single-center experi-ence. Transplantation 2006; 81: 1285-1289. (Pubitemid 43804548)
76. Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, Kapur S, Ilsley JN, Kistler KD, Cosimi AB: Thymoglobulin antibody immunosuppression in living donor recipi-ents investigators. antithymocyte globulin in-duction in living donor renal transplant re-cipients: final report of the Tailor Registry. Transplantation 2012; 94: 331-337.
77. Schenker P, Ozturk A, Vonend O, Krüger B, Jazra M, Wunsch A, Krämer B, Viebahn R Single-dose thymoglobulin induction in liv-ing-donor renal transplantation. Ann Trans-plant 2011; 16: 50-58.
78. Ciancio G, Gaynor JJ, Roth D, Kupin W, Han-son L, Tueros L, Zarak A, Ruiz P, Burke GW 3rd: Randomized trial of thymoglobulin ver-sus alemtuzumab (with lower dose mainte-nance immunosuppression) versus daclizu-mab in living donor renal transplantation. Transplant Proc 2010; 42: 3503-3506.
79. Martins L, Fonseca I, Almeida M, Henriques AC, Dias L, Sarmento AM, Cabrita A: Immu-nosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc 2005; 37: 2755-2758. (Pubitemid 41354727)
80. Abouna GM, Kumar MS, Stephan R, Prior JE, Lyons P, Bulova SI, al-Abdullah IH: Induc-tion therapy with ATG reduces the incidence of allograft rejection and improves graft sur-vival in cadaver renal transplantation. Trans-plant Proc 1993; 25: 2241-2242. (Pubitemid 23194080)
81. Willoughby LM, Schnitzler MA, Brennan DC, Pinsky BW, Dzebisashvili N, Buchanan PM, Neri L, Rocca-Rey LA, Abbott KC, Len-tine KL: Early outcomes of thymoglobulin and basiliximab induction in kidney trans-plantation: application of statistical ap-proaches to reduce bias in observational com-parisons. Transplantation 2009; 87: 1520-1529.
82. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, Charpentier B, Tou-chard G, Berthoux F, Merville P, Ouali N Squifflet JP, Bayle F, Wissing KM, Hazzan M: Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant re-cipients. J Am Soc Nephrol 2009; 20: 1385-1392.
83. Morgan RD, O'Callaghan JM, Knight SR Morris PJ: Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 2012; 93: 1179-1188.
84. Hale G, Xia MQ, Tighe HP, Dyer MJ, Wald-mann H: The Campath-1 antigen (CDw52). Tissue Antigens 1990; 35: 118-127. (Pubitemid 20152978)
85. Fox EJ: Alemtuzumab in the treatment of re-lapsing-remitting multiple sclerosis. Expert Rev Neurother 2010; 10: 1789-1797.
86. Kanda J, Lopez RD, Rizzieri DA: Alemtu-zumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 2011; 93: 586-593.
87. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK: Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509-1512. (Pubitemid 46934076)
88. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R Holman J, INTAC Study Group: Alemtuzu-mab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
89. Goh BK, Chedid MF, Gloor JM, Raghavaiah S, Stegall MD: The impact of terminal com-plement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globu-lin in living donor renal allografts. Transpl Immunol 2012; 27: 95-100.
90. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated re-jection in sensitized renal transplant recipi-ents. Am J Transplant 2011; 11: 2405-2413.
91. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K: Posttransplant lymphoprolifera-tive disorders after renal transplantation in the United States in era of modern immuno-suppression. Transplantation 2005; 80: 1233-1243. (Pubitemid 41746802)
92. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW: Asso-ciation of the type of induction immunosup-pression with posttransplant lymphoprolif-erative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293. (Pubitemid 37430713)
93. Opelz G, Daniel V, Naujokat C, Döhler B: Ep-idemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
94. Shahinian VB, Muirhead N, Jevnikar AM, Leckie SH, Khakhar AK, Luke PP, Rizkalla KS, Hollomby DJ, House AA: Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative dis-order in adult renal allograft recipients. Transplantation 2003; 75: 851-856. (Pubitemid 36373459)
95. Opelz G DB: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
96. Shroff R Rees L: The post-transplant lympho-proliferative disorder-a literature review. Pediatr Nephrol 2004; 19: 369-377. (Pubitemid 38477398)
97. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B: Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipi-ents. Transplantation 2006; 81: 1227-1233. (Pubitemid 43804539)
98. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM: Post-transplant lymphoproliferative disor-ders following liver transplantation: inci-dence, risk factors and survival. Am J Trans-plant 2006; 6: 1017-1024. (Pubitemid 44356653)
99. Dharnidharka VR, Stevens G: Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622-626. (Pubitemid 41413502)
100. Nee R, Hurst FP, Dharnidharka VR, Jindal RM, Agodoa LY, Abbott KC: Racial varia-tion in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011; 92: 190-195.
101. Hardinger KL, Rhee S, Buchanan P, Koch M, Miller B, Enkvetchakul D, Schuessler R Schnitzler MA, Brennan DC: A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction Immunosuppressive therapy: 10 year re-sults. Transplantation 2008; 86: 947-952.
102. Kirk A, Cherikh W, Ring M, Burke G, Kaufman D, Knechtle S, Potdar S, Shapiro R Dharnidharka V, Kauffman H: Dissociation of T-cell depletion and post-transplant lym-phoproliferative disease in kidney recipients treated with alemetuzumab. Am J Trans-plant 2007; 7: 2619-2625. (Pubitemid 47561615)
103. Gurk-Turner C, Airee R, Philosophe B, Ku-kuruga D, Drachenberg C, Haririan A: Thy-moglobulin dose optimization for induction therapy in high-risk kidney transplant recip-ients. Transplantation 2008; 85: 1425-1430.
104. Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, Pankewycz O: Low-dose thymoglobulin use in elderly renal trans-plant recipients is safe and effective induc-tion therapy. Transplant Proc 2011; 43: 466-468.
105. Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, Lowell JA, Shenoy S, Howard TK, Ramachandran V, Irish W, Schnitzle MA, Brennan DC: Short course in-duction immunosuppression with thymo-globulin for renal transplant recipients. Transplantation 2002; 73: 473-475. (Pubitemid 34174301)
106. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC: A randomized, prospective, pharmacoeco-nomic trial of tacrolimus versus cyclospo-rine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005; 80: 41-46. (Pubitemid 40980893)
107. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3 lymphocyte counts in kidney and kid-ney-pancreas transplant recipients. Trans-plantation 2002; 73: 1514-1518. (Pubitemid 34547476)
108. Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, Cardarelli F, Winkelmayer WC, Cosimi AB, Tolkoff-Ru-bin N: Comparison of two dosages of thy-moglobulin used as a short-course for in-duction in kidney transplantation. Transpl Int 2006; 19: 629-635.
109. Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, Ternant D, Foulon C Pilorge B, Lemay D, Sung C, Halimi JM, Bar-on C, Lebranchu Y: Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte antiglobulin dosing regimens: results of a randomized trial. Transpl Immunol 2013; 28: 120-126.
110. Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O: Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc 2011; 43: 458-461.
111. Djamali A, Turc-Baron C, Portales P, Lever-son G, Chong G, Clot J, Mourad G: Low-dose antithymocyte globulins in renal trans-plantation: daily versus intermittent admin-istration based on T-cell monitoring. Transplantation 2000; 69: 799-805. (Pubitemid 30174100)
112. Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC: Reduced dose rab-bit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplanta-tion 2009; 88: 891-896.
113. Deeks ED, Keating G: Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute re-nal allograft rejection. Drugs 2009; 69: 1483-1512.
114. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Co-sio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial compar-ing sirolimus and tacrolimus. Am J Trans-plant 2006; 6: 514-522. (Pubitemid 43382137)